PRESTIGE CONSUMER HEALTHCARE INC (PBH)
Health Care · consumer health and OTC products · NYSE
Prestige Consumer Healthcare is a branded OTC healthcare company that manages a diverse portfolio of essential household and personal care products.
What PRESTIGE CONSUMER HEALTHCARE INC does
Prestige Consumer Healthcare Inc. is a marketer and distributor of over-the-counter (OTC) healthcare and household cleaning products. The company manages a portfolio of well-known consumer brands across categories including eye care, oral care, pain relief, and digestive health. Its products are sold primarily through retail channels in the United States and international markets.
Themes: consumer health, OTC medications, personal care and hygiene, brand management
Fundamentals
- Price$51.31 as of 2026-08-21 close
- Market cap$2.4B as of 2026-08-21
- 1-year return-21.6% 2025-08-21 close $65.45 → 2026-08-21 close $51.31
- P/E14.06 as of 2026-08-24
- Net margin+15.6% as of 2026-08-24
- Gross margin+53.5% as of 2026-08-24
- ROE+9.2% as of 2026-08-24
- Debt / equity1.06 as of 2026-08-24
- Revenue growth (YoY)-1.4% as of 2026-08-24
- Revenue CAGR (3y)-1.2% SEC XBRL
- Beta0.33 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How PBH compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
PBH is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
42.5 #1272 of 1,704 scored · #207 of 240 in Health Care
Setup 55th: no fresh 20-day breakout up or down; momentum 52nd: near the bottom of its 14-day range (oversold); weakest is volume and participation 26th: trading volume is about normal versus its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How PRESTIGE CONSUMER HEALTHCARE INC looks technically
PRESTIGE CONSUMER HEALTHCARE INC (PBH) is trading 10.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 264 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It made a new 20-day high about 11 trading days ago. It is 27.8% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 10.6% below its 200-day average, the long-term trend line — a long-term downtrend | -10.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $49.71 | $49.71 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $57.39 | $57.39 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 55.98. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 264 trading days ago — a "death cross", a bearish long-term signal | 264 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 17.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 51.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($49.73 to $55.98) — its "stochastic" reading is 25 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 25.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $71.07 | $71.07 |
|---|---|---|
| From the 52-week high | it is 27.8% below its 52-week high (its highest price of the past year) | -27.8% |
| Above the 52-week low | it is 20.1% above its 52-week low (its lowest price of the past year) | +20.1% |
| Below the 52-week high | it is 27.8% below its highest point of the past year | 27.8% |
| Since a 20-day breakout | it made a new 20-day high about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day high about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $90.04 (set on 2025-03-10) | $90.04 |
| Given back of the 52-week move | over the past year its closes ranged ($45.44 to $70.21), and it has recovered roughly a quarter of its fall from last year’s high — 24% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $60.75 to $61.54. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 23.7% |
| From the all-time high | it is 43.0% below its all-time high | -43.0% |
| Nearest price level | it is sitting right on a resistance level at $51.41 — a price it turned at twice since 2026-04-06, most recently on 2026-07-17. Since 2024-08-21 it has 1 such level below the current price and 15 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.2% |
| All-time low | its lowest closing price on record is $3.92 (set on 2009-03-12) | $3.92 |
| Above the all-time low | it is 1208.9% above its all-time low | +1,209% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 37th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.79 between its high and its low — about 3.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.79 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $49.08 and $54.56 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $49.08 – $51.82 – $54.56 |
| Typical daily range (% of price) | its price moves about 3.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.5% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges below its 200-day average price (10.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.79× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
|---|---|---|
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|---|---|
| Gap filled | a 4.6% gap up opened on 2026-08-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 2.3 percentage points (the stock gained 4.7% while the market gained 2.3%) | +2.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 3.3 percentage points (the stock gained 6.4% while the market gained 3.1%) | +3.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 37.3 percentage points (the stock lost 26.3% while the market gained 11.1%) | -37.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 42.1 percentage points (the stock lost 21.6% while the market gained 20.5%) | -42.1% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.9% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.8% of the share price. | +0.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $54.58 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -6.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $52.29 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -1.9% |
Price levels it has turned at before
PBH last closed at $51.31 on 2026-08-21. Since 2024-08-21 it has turned at 1 price below its last close and 15 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $51.41 | Resistance | 0.2% above the last close | turned there twice · 2026-04-06 to 2026-07-17 |
| $49.46 | Support | 3.6% below the last close | turned there three times · 2026-05-27 to 2026-06-26 |
| $60.20 | Resistance | 17.3% above the last close | turned there three times · 2025-10-13 to 2026-04-27 |
| $62.24 | Resistance | 21.3% above the last close | turned there five times · 2025-08-12 to 2026-01-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $55.98.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market · Printed a bullish engulfing pair · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.71 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$67.80 range $55.00 – $75.00; median $70.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PBH
- Consensus EPS estimate$1.07 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on a limited number of third-party manufacturers, which has led to product shortages and supply chain disruptions.","Significant concentration risk with a single supplier accounting for over 20% of gross revenues.","Potential for product quality issues, regulatory actions, or recalls if third-party manufacturers fail to comply with FDA or other standards."]
What changed in the latest 10-Q
AI-assisted comparison of PBH's 10-Q filed 2026-02-05 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- New section 'Acquisition' describing completion of Pillar5 Pharma, Inc. acquisition on December 18, 2025, funded through cash on hand and existing asset-based revolving credit facility (filed 2026-02-05)
- Statement that Pillar5 is based in Ontario, Canada and is a leading sterile ophthalmic manufacturer and current Clear Eyes supplier (filed 2026-02-05)
- Statement that pro-forma effect of Pillar5 acquisition on revenues and earnings was not material (filed 2026-02-05)
- Reference to acquisition details in Note 2 of unaudited Condensed Consolidated Financial Statements (filed 2026-02-05)
- Removed:
- Cautionary Statement Regarding Forward-Looking Statements reference changed from page 31 to page 33 (filed 2026-02-05)
- Reworded:
- Economic Environment section: 'These shortages have negatively impacted our results of operations, and we expect further shortages will continue to have a negative impact on our sales' (2026-02-05) changed from 'These shortages negatively impacted our results of operations, and we expect further shortages may have a negative impact on our sales' (2025-11-06) - shift from conditional 'may' to assertive 'will continue'
- Results of Operations comparison period changed from 'Three Months Ended September 30, 2025 compared to Three Months Ended September 30, 2024' (2025-11-06) to 'Three Months Ended December 31, 2025 compared to Three Months Ended December 31, 2024' (2026-02-05)
- Total Segment Revenues table now shows December 31 comparison data instead of September 30 comparison data (filed 2026-02-05)
- Notes:
- Older filing appears truncated at end of Results of Operations section; comparison limited to content available
- International OTC Healthcare and consolidated revenue sections present in older filing are not shown in newer filing excerpt, preventing full comparison of those sections
Risk Factors
- Added:
- Newer filing (2026-02-05) includes nine-month financial data ending December 31, 2025, whereas older filing (2025-11-06) only reported six-month data ending September 30, 2025
- Newer filing includes Item 5 table of contents reference removed; older filing listed 'Item 5. Other Information' at page 34
- Newer filing reports quarterly and nine-month net sales of $283,045 thousand and $806,082 thousand respectively for periods ending December 31, 2025
- Newer filing reports nine-month net income of $136,373 thousand for period ending December 31, 2025
- Newer filing shows December 31, 2025 balance sheet with total assets of $3,494,743 thousand
- Newer filing includes write-off of supplier loan of $10,332 thousand in nine-month operating activities
- Removed:
- Older filing (2025-11-06) included 'Item 5. Other Information' at page 34, removed in newer filing (2026-02-05)
- Older filing reported quarterly and six-month net sales of $273,759 thousand and $523,037 thousand respectively for periods ending September 30, 2025
- Reworded:
- Item 1A. Risk Factors page number changed from 33 (older filing, 2025-11-06) to 35 (newer filing, 2026-02-05)
- Item 2. Unregistered Sales of Equity Securities and Use of Proceeds page number changed from 34 (older filing, 2025-11-06) to 36 (newer filing, 2026-02-05)
- Item 6. Exhibits page number changed from 35 (older filing, 2025-11-06) to 37 (newer filing, 2026-02-05)
- Signatures page number changed from 36 (older filing, 2025-11-06) to 38 (newer filing, 2026-02-05)
- Financial statement periods changed from 'Three Months Ended September 30' and 'Six Months Ended September 30' (older filing, 2025-11-06) to 'Three Months Ended December 31' and 'Nine Months Ended December 31' (newer filing, 2026-02-05)
- Balance sheet comparison date changed from 'September 30, 2025' (older filing, 2025-11-06) to 'December 31, 2025' (newer filing, 2026-02-05)
- Commitments and Contingencies reference changed from 'Note 14' (older filing, 2025-11-06) to 'Note 15' (newer filing, 2026-02-05)
- Cash flows statement periods changed from 'Six Months Ended September 30' (older filing, 2025-11-06) to 'Nine Months Ended December 31' (newer filing, 2026-02-05)
- Notes:
- The newer filing text appears truncated at the end of the cash flows statement; comparison limited to available text
- The older filing text also appears truncated at the end of the cash flows statement; full cash flows comparison not possible
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 4 sells ($120444) — 1 selling insider
Most recent open-market transaction: 2026-05-11. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PBH's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PBH as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,671,405
- Reported value $573,224,188
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PBH had 3,819,116 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PBH had 8.06% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.1 days to cover at the same settlement.
- Reported short interest (shares) 3,819,116
- Short interest (% of shares outstanding) 8.06%
- Prior settlement (shares) 3,087,049
- Reported change 23.71%
- Days to cover (reported) 8.1
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Kenvue (KVUE)
- Haleon
- Church & Dwight (CHD)
- Johnson & Johnson (JNJ)
- Perrigo (PRGO)
- Sanofi (SNY)
- Bausch Health (BHC)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PBH vs…
Frequently asked questions
What does PRESTIGE CONSUMER HEALTHCARE INC (PBH) do?
Prestige Consumer Healthcare Inc. is a marketer and distributor of over-the-counter (OTC) healthcare and household cleaning products. The company manages a portfolio of well-known consumer brands across categories including eye care, oral care, pain relief, and digestive health. Its products are sold primarily through retail channels in the United States and international markets.
What sector is PRESTIGE CONSUMER HEALTHCARE INC (PBH) in?
PRESTIGE CONSUMER HEALTHCARE INC (PBH) is classified in the Health Care sector. Its industry is consumer health and OTC products. It trades on NYSE.
Who are PRESTIGE CONSUMER HEALTHCARE INC's (PBH) competitors?
Notable peers of PRESTIGE CONSUMER HEALTHCARE INC (PBH) include Kenvue, Haleon, Church & Dwight, Johnson & Johnson and Perrigo. This peer set is informational only — not financial advice.
Is PRESTIGE CONSUMER HEALTHCARE INC (PBH) overbought or oversold right now?
PRESTIGE CONSUMER HEALTHCARE INC (PBH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PBH come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.